Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives Consensus Rating of "Hold" from Analysts

Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report) has received a consensus rating of "Hold" from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $1.35.

Several research analysts have weighed in on the company. Wells Fargo & Company lowered their price target on Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 14th. Barclays reduced their target price on Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research note on Wednesday, May 14th. HC Wainwright reduced their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Jones Trading downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Finally, Mizuho downgraded Adaptimmune Therapeutics from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $1.50 to $0.50 in a research note on Thursday, June 26th.

Adaptimmune Therapeutics Stock Up 4.4%

Shares of NASDAQ:ADAP traded up $0.01 during trading on Thursday, hitting $0.35. 1,102,004 shares of the company were exchanged, compared to its average volume of 690,318. The stock has a market cap of $91.95 million, a price-to-earnings ratio of -1.28 and a beta of 2.18. Adaptimmune Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.48. The firm has a fifty day moving average price of $0.27 and a two-hundred day moving average price of $0.37. The company has a current ratio of 2.02, a quick ratio of 1.79 and a debt-to-equity ratio of 4.24.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). The firm had revenue of $7.29 million for the quarter, compared to analyst estimates of $6.55 million. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 38.91%. As a group, research analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Adaptimmune Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP raised its holdings in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares in the last quarter. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 21,688 shares in the last quarter. Invesco Ltd. raised its holdings in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. 31.37% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.